Oral News and Research

RSS

FDA and EMA accept Novartis' regulatory application for siponimod to treat SPMS in adults

Novartis today announced that both the US Food and Drug Administration and European Medicines Agency have accepted the company's New Drug Application and Marketing Authorization Application respectively, for investigational oral, once-daily siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis in adults.

8 Oct 2018

New blood test may detect early-stage lung cancer when surgical intervention is not possible

Non-small-cell lung carcinoma is often fatal because most cases are not diagnosed until they are so advanced that surgical intervention is no longer possible. To improve outcomes researchers are developing a blood test to detect lung cancer earlier in the disease.

8 Oct 2018

Periodontal disease may be an initiator of Alzheimer's

Long-term exposure to periodontal disease bacteria causes inflammation and degeneration of brain neurons in mice that is similar to the effects of Alzheimer's disease in humans, according to a new study from researchers at the University of Illinois at Chicago.

4 Oct 2018

Vaxart to present new data from Phase 2 Challenge Study of H1 influenza oral tablet vaccine

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced it will present new data from the Phase 2 Challenge Study of its H1 influenza oral tablet vaccine at IDWeek 2018 in San Francisco on Saturday, October 6, 2018.

4 Oct 2018

Genentech announces Phase III study results of baloxavir marboxil in people at high risk of flu

Genentech, a member of the Roche Group, today announced that the Phase III CAPSTONE-2 study showed treatment with baloxavir marboxil significantly reduced the time to improvement of influenza symptoms versus placebo in people at high risk of serious complications from the flu, which includes adults 65 years of age or older, or those who have conditions such as asthma, chronic lung disease, morbid obesity, or heart disease.

4 Oct 2018

Genentech announces clinical data from studies investigating risdiplam in spinal muscular atrophy

Genentech, a member of the Roche Group, announced today interim clinical data from the dose-finding parts of the pivotal FIREFISH and SUNFISH studies investigating risdiplam in spinal muscular atrophy.

3 Oct 2018

Carnegie professor receives NIH Director's New Innovator Award

Kathryn Whitehead, assistant professor of chemical engineering at Carnegie Mellon University, has been awarded a 2018 National Institutes of Health (NIH) Director's New Innovator Award for her project titled "Fate, Function, and Genetic Engineering of Breast Milk Cells for Infant Therapy."

3 Oct 2018

Disruption in combination inhaled corticosteroid therapy may impact patients' symptoms and disease control

Disruption of the refill of patients' regular combination inhaled corticosteroid therapy brand may have impacted symptoms and disease control and potentially lead to an increased rate of costly exacerbations and hospitalizations.

2 Oct 2018

Study using DFMO shows positive results for children with high risk neuroblastoma

A paper published September 27 in Scientific Reports shows the positive results of a phase II clinical trial using the oral medication DFMO to prevent relapse in children with High Risk Neuroblastoma.

1 Oct 2018

Researchers identify genes that could help predict treatment outcomes for parasitic disease

Researchers at the University of York have identified genes in a parasite that could help clinicians predict drug treatment outcomes for patients with visceral leishmaniasis in Brazil.

1 Oct 2018

Eisai's antiepileptic drug receives FDA approval to treat partial-onset seizures in pediatric patients

Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. received approval from the U.S. Food and Drug Administration for an indication expansion for Eisai's antiepileptic drug Fycompa (perampanel) to cover partial-onset seizures in pediatric patients with epilepsy 4 years of age and older.

1 Oct 2018

Study shows Bartonella infections in vampire bats are highly prevalent in Peru and Belize

Bartonella are bacteria that cause endocarditis, a potentially life-threatening illness in humans and domestic animals.

29 Sep 2018

Verastem Oncology selects US Bioservices to dispense COPIKTRA capsules

US Bioservices, a specialty pharmacy that is a part of AmerisourceBergen, today announced that it has been selected by Verastem OncologyTM to dispense COPIKTRA (duvelisib) capsules.

28 Sep 2018

Ovarian cancer risk reduced among women taking modern combined oral contraceptive pills

According to a new study women of reproductive age who are using the modern oral contraceptive pills or patches and rings that contain a combination of estrogen and progesterone are at a reduced risk for ovarian cancer. The study was published in the recent issue of the British Medical Journal (BMJ).

27 Sep 2018

Bioaxone Biosciences receives Fast-Track SBIR grant to assess potential of Rho Kinase 2 inhibitor

BioAxone BioSciences, Inc. announced today the receipt of a Fast-Track grant from the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, as part of the agency's Small Business Innovation Research Program.

27 Sep 2018

FLX Bio treats first patient in its Phase 1/2 clinical trial of FLX475 for treating various advanced cancers

FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist that selectively inhibits migration of regulatory T cells into the tumor microenvironment.

27 Sep 2018

Decibel obtains exclusive license to commercialize ORC-13661 for preventing hearing, balance disorders

Decibel Therapeutics and Oricula Therapeutics today announced that Decibel has obtained an exclusive, worldwide license to the development and commercialization of ORC-13661, an oral medication developed by Oricula Therapeutics for the prevention of hearing loss and balance disorders that can occur following treatment of severe infections with aminoglycoside antibiotics.

27 Sep 2018

Oral News and Research

FDA and EMA accept Novartis' regulatory application for siponimod to treat SPMS in adults

New blood test may detect early-stage lung cancer when surgical intervention is not possible

Periodontal disease may be an initiator of Alzheimer's

Vaxart to present new data from Phase 2 Challenge Study of H1 influenza oral tablet vaccine

Genentech announces Phase III study results of baloxavir marboxil in people at high risk of flu

Genentech announces clinical data from studies investigating risdiplam in spinal muscular atrophy

Carnegie professor receives NIH Director's New Innovator Award

Disruption in combination inhaled corticosteroid therapy may impact patients' symptoms and disease control

Study using DFMO shows positive results for children with high risk neuroblastoma

Researchers identify genes that could help predict treatment outcomes for parasitic disease

Eisai's antiepileptic drug receives FDA approval to treat partial-onset seizures in pediatric patients

Study shows Bartonella infections in vampire bats are highly prevalent in Peru and Belize

Verastem Oncology selects US Bioservices to dispense COPIKTRA capsules

Ovarian cancer risk reduced among women taking modern combined oral contraceptive pills

Bioaxone Biosciences receives Fast-Track SBIR grant to assess potential of Rho Kinase 2 inhibitor

FLX Bio treats first patient in its Phase 1/2 clinical trial of FLX475 for treating various advanced cancers

Decibel obtains exclusive license to commercialize ORC-13661 for preventing hearing, balance disorders

No scientific reason available to assume link between BPA uptake and MIH in children

Research findings could bring relief to millions of cancer patients undergoing chemotherapy

Researchers develop promising allergy vaccine for hay fever

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News